Taiwan consensus statement on the management of chronic hepatitis B.

[1]  J. Kao.  Hepatitis B: From control to cure. , 2018, Journal of the Formosan Medical Association = Taiwan yi zhi.

[2]  Y. Liaw,et al.  Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen–negative chronic hepatitis B , 2018, Hepatology.

[3]  Y. Liaw,et al.  Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B. , 2018, Journal of the Formosan Medical Association = Taiwan yi zhi.

[4]  Y. Liaw,et al.  HBsAg Kinetics in Retreatment Decision for Off-Therapy Hepatitis B Flare in HBeAg-Negative Patients. , 2018, Gastroenterology.

[5]  T. Tseng,et al.  Fibrosis‐4 index predicts cirrhosis risk and liver‐related mortality in 2075 patients with chronic HBV infection , 2018, Alimentary pharmacology & therapeutics.

[6]  T. Hu,et al.  The incidence and predictors of HBV relapse after cessation of tenofovir therapy in chronic hepatitis B patients , 2018, Journal of viral hepatitis.

[7]  T. Hu,et al.  Long-term incidence and predictors of hepatitis B surface antigen loss after discontinuing nucleoside analogues in noncirrhotic chronic hepatitis B patients. , 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[8]  T. Berg,et al.  Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients - FINITE study. , 2017, Journal of hepatology.

[9]  Ding‐Shinn Chen,et al.  Fibrosis-4 Index Helps Identify HBV Carriers With the Lowest Risk of Hepatocellular Carcinoma , 2017, The American Journal of Gastroenterology.

[10]  Thomas Berg,et al.  EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. , 2017, Journal of hepatology.

[11]  Yi‐Hsiang Huang,et al.  Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Biologics Treatment , 2016, The Journal of infectious diseases.

[12]  Y. Liaw,et al.  Clinical Relapse After Cessation of Tenofovir Therapy in Hepatitis B e Antigen-Negative Patients. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[13]  T. Tseng,et al.  Four‐year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[14]  M. Manns,et al.  Viral and Host Responses After Stopping Long-term Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B. , 2016, The Journal of infectious diseases.

[15]  John F. Flaherty,et al.  Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. , 2016, The lancet. Gastroenterology & hepatology.

[16]  H. Hsu,et al.  Entecavir Treatment in Children and Adolescents with Chronic Hepatitis B Virus Infection. , 2016, Pediatrics and neonatology.

[17]  Q. Ning,et al.  Response-guided peginterferon therapy in patients with HBeAg-positive chronic hepatitis B: A randomized controlled study. , 2016, Journal of hepatology.

[18]  M. Yuen,et al.  Hepatitis B surface antigen seroclearance during nucleoside analogue therapy: surface antigen kinetics, outcomes, and durability , 2016, Journal of Gastroenterology.

[19]  M. Buti,et al.  PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. , 2016, Journal of hepatology.

[20]  Chien-Jen Chen,et al.  Incorporating Serum Level of Hepatitis B Surface Antigen or Omitting Level of Hepatitis B Virus DNA Does not Affect Calculation of Risk for Hepatocellular Carcinoma in Patients Without Cirrhosis. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[21]  V. Kim,et al.  Pegylated interferon alfa for chronic hepatitis B: systematic review and meta‐analysis , 2016, Journal of viral hepatitis.

[22]  F. Sun,et al.  Systematic review with meta‐analysis: the diagnostic accuracy of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B , 2016, Alimentary pharmacology & therapeutics.

[23]  N. Terrault,et al.  AASLD guidelines for treatment of chronic hepatitis B , 2016, Hepatology.

[24]  B. McMahon,et al.  Antiviral therapy in management of chronic hepatitis B viral infection in children: A systematic review and meta‐analysis , 2016, Hepatology.

[25]  M. Kumar,et al.  Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update , 2015, Hepatology International.

[26]  R. Chien,et al.  Clinical outcomes after interruption of entecavir therapy in HBeAg‐negative chronic hepatitis B patients with compensated cirrhosis , 2015, Alimentary pharmacology & therapeutics.

[27]  Sheng-Nan Lu,et al.  Association Between Level of Hepatitis B Surface Antigen and Relapse After Entecavir Therapy for Chronic Hepatitis B Virus Infection. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[28]  J. Kao,et al.  Successful treatment of chronic hepatitis B and D with pegylated-interferon plus entecavir. , 2015, Journal of the Formosan Medical Association = Taiwan yi zhi.

[29]  T. Therneau,et al.  Impact of long‐term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B , 2015, Cancer.

[30]  J. Kao,et al.  Serum Biomarkers Predictive of Significant Fibrosis and Cirrhosis in Chronic Hepatitis B , 2015, Journal of clinical gastroenterology.

[31]  Y. Ding,et al.  Efficacy and safety of telbivudine treatment: an open‐label, prospective study in pregnant women for the prevention of perinatal transmission of hepatitis B virus infection , 2015, Journal of viral hepatitis.

[32]  Mei-Hwei Chang,et al.  Efficacy of maternal tenofovir disoproxil fumarate in interrupting mother‐to‐infant transmission of hepatitis B virus , 2015, Hepatology.

[33]  Jialing Zhou,et al.  A Better Antiviral Efficacy Found in Nucleos(t)ide Analog (NA) Combinations with Interferon Therapy than NA Monotherapy for HBeAg Positive Chronic Hepatitis B: A Meta-Analysis , 2015, International journal of environmental research and public health.

[34]  Y. Xiang,et al.  The Efficacy and Safety of Entecavir and Interferon Combination Therapy for Chronic Hepatitis B Virus Infection: A Meta-Analysis , 2015, PloS one.

[35]  H. Whittle,et al.  Natural history of chronic HBV infection in West Africa: a longitudinal population-based study from The Gambia , 2015, Gut.

[36]  Asociacion Latinoamericana para el Estudio del Higado.  EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. , 2015, Journal of hepatology.

[37]  D. Podzamczer,et al.  Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials , 2015, The Lancet.

[38]  J. Sheng,et al.  Associations between hepatitis B virus basal core promoter/pre-core region mutations and the risk of acute-on-chronic liver failure: a meta-analysis , 2015, Virology Journal.

[39]  Chien-Jen Chen,et al.  Predicting Hepatitis B Virus (HBV) Surface Antigen Seroclearance in HBV e Antigen-Negative Patients With Chronic Hepatitis B: External Validation of a Scoring System. , 2015, The Journal of infectious diseases.

[40]  J. Kao,et al.  Hepatitis B virus genotypes and variants. , 2015, Cold Spring Harbor perspectives in medicine.

[41]  K. Simon,et al.  Adding pegylated interferon to entecavir for hepatitis B e antigen–positive chronic hepatitis B: A multicenter randomized trial (ARES study) , 2015, Hepatology.

[42]  Tsuyoshi Shiina,et al.  WFUMB guidelines and recommendations for clinical use of ultrasound elastography: Part 3: liver. , 2015, Ultrasound in medicine & biology.

[43]  A. Ray,et al.  Implications of Efficient Hepatic Delivery by Tenofovir Alafenamide (GS-7340) for Hepatitis B Virus Therapy , 2015, Antimicrobial Agents and Chemotherapy.

[44]  H. Lee,et al.  Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial , 2015, Gut.

[45]  John F. Flaherty,et al.  Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. , 2015, Journal of hepatology.

[46]  M. Buti,et al.  Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (≥ 9 log10 copies/ml) , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[47]  H. Lee,et al.  Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial , 2015, Gut.

[48]  J. Kao,et al.  Improving clinical outcomes of chronic hepatitis B virus infection , 2015, Expert review of gastroenterology & hepatology.

[49]  Q. Ning,et al.  Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues , 2015, Gut.

[50]  Huy A. Nguyen,et al.  Safety and efficacy of entecavir in adefovir‐experienced patients , 2015, Journal of gastroenterology and hepatology.

[51]  M. Buti,et al.  Seven-Year Efficacy and Safety of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection , 2014, Digestive Diseases and Sciences.

[52]  Tongyu Lin,et al.  Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial. , 2014, JAMA.

[53]  H. Chan,et al.  A randomized, open-label clinical study of combined pegylated interferon Alfa-2a (40KD) and entecavir treatment for hepatitis B "e" antigen-positive chronic hepatitis B. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[54]  J. Gallant,et al.  Discontinuation of Tenofovir Disoproxil Fumarate for Presumed Renal Adverse Events in Treatment-Naïve HIV-1 Patients: Meta-analysis of Randomized Clinical Studies , 2014, HIV clinical trials.

[55]  K. Simon,et al.  Polymorphisms of HLA‐DP are associated with response to peginterferon in Caucasian patients with chronic hepatitis B , 2014, Alimentary pharmacology & therapeutics.

[56]  Q. Ning,et al.  Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial). , 2014, Journal of hepatology.

[57]  E. Cholongitas,et al.  New nucleos(t)ide analogue monoprophylaxis after cessation of hepatitis B immunoglobulin is effective against hepatitis B recurrence , 2014, Transplant international : official journal of the European Society for Organ Transplantation.

[58]  Guohong Deng,et al.  Effect of HLA‐DP and IL28B gene polymorphisms on response to interferon treatment in hepatitis B e‐antigen seropositive chronic hepatitis B patients , 2014, Hepatology research : the official journal of the Japan Society of Hepatology.

[59]  Young Youn Cho,et al.  Efficacy of Entecavir-Tenofovir Combination Therapy for Chronic Hepatitis B Patients with Multidrug-Resistant Strains , 2014, Antimicrobial Agents and Chemotherapy.

[60]  Michael D. Miller,et al.  HBV clinical isolates expressing adefovir resistance mutations show similar tenofovir susceptibilities across genotypes B, C and D , 2014, Liver international : official journal of the International Association for the Study of the Liver.

[61]  J. Hwang,et al.  Effect of Virological Response to Entecavir on the Development of Hepatocellular Carcinoma in Hepatitis B Viral Cirrhotic Patients: Comparison Between Compensated and Decompensated Cirrhosis , 2014, The American Journal of Gastroenterology.

[62]  Sheng-Nan Lu,et al.  Antiviral effect of entecavir in nucleos(t)ide analogue‐naïve and nucleos(t)ide analogue‐experienced chronic hepatitis B patients without virological response at week 24 or 48 of therapy , 2014, Journal of viral hepatitis.

[63]  M. Kudo,et al.  Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. , 2014, JAMA.

[64]  P. Faure,et al.  Prospective evaluation of FibroTest®, FibroMeter®, and HepaScore® for staging liver fibrosis in chronic hepatitis B: comparison with hepatitis C. , 2014, Journal of hepatology.

[65]  Chien-Jen Chen,et al.  Distinct seromarkers predict different milestones of chronic hepatitis B progression , 2014, Hepatology.

[66]  Sheng-Nan Lu,et al.  Serum hepatitis B surface antigen levels predict treatment response to nucleos(t)ide analogues. , 2014, World journal of gastroenterology.

[67]  Pei-Jer Chen,et al.  Chemotherapy‐induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study , 2014, Hepatology.

[68]  Sheng-Nan Lu,et al.  Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation. , 2014, Journal of hepatology.

[69]  V. Wong,et al.  Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study , 2014, Gut.

[70]  I. Hung,et al.  Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment , 2014, Journal of gastroenterology and hepatology.

[71]  H. Chan,et al.  Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA. , 2014, Gastroenterology.

[72]  Chao-Long Chen,et al.  Section 14. Combination of Entecavir Plus Low-Dose On-Demand Hepatitis B Immunoglobulin is Effective With Very Low Hepatitis B Recurrence After Liver Transplantation , 2014, Transplantation.

[73]  Ding‐Shinn Chen,et al.  Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers , 2014, Gut.

[74]  M. Manns,et al.  Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients. , 2014, Journal of hepatology.

[75]  H. Lee,et al.  Assessment of current criteria for primary nonresponse in chronic hepatitis B patients receiving entecavir therapy , 2014, Hepatology.

[76]  A. Horban,et al.  Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. , 2014, Gastroenterology.

[77]  J.H. Cho,et al.  Successful withdrawal of antiviral treatment in kidney transplant recipients with chronic hepatitis B viral infection , 2014, Transplant infectious disease : an official journal of the Transplantation Society.

[78]  P. Lampertico,et al.  Systematic review with meta‐analysis: do interferon lambda 3 polymorphisms predict the outcome of interferon‐therapy in hepatitis B infection? , 2014, Alimentary pharmacology & therapeutics.

[79]  Chien-Hung Chen,et al.  Comparing the efficacy and clinical outcome of telbivudine and entecavir naïve patients with hepatitis B virus‐related compensated cirrhosis , 2014, Journal of gastroenterology and hepatology.

[80]  T. Hu,et al.  A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match-control study. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[81]  G. Wong,et al.  Non‐invasive algorithm of enhanced liver fibrosis and liver stiffness measurement with transient elastography for advanced liver fibrosis in chronic hepatitis B , 2014, Alimentary pharmacology & therapeutics.

[82]  J. Kao,et al.  Higher adherence with 3‐year entecavir treatment than lamivudine or telbivudine in treatment‐naïve Taiwanese patients with chronic hepatitis B , 2014, Journal of gastroenterology and hepatology.

[83]  C. Chu,et al.  Off‐therapy durability of response to entecavir therapy in hepatitis B e antigen‐negative chronic hepatitis B patients , 2013, Hepatology.

[84]  V. Wong,et al.  Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients With liver cirrhosis , 2013, Hepatology.

[85]  H. Lee,et al.  HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability , 2013, Gut.

[86]  Han‐Chieh Lin,et al.  CXCL9 Associated with Sustained Virological Response in Chronic Hepatitis B Patients Receiving Peginterferon Alfa-2a Therapy: A Pilot Study , 2013, PloS one.

[87]  P. Snelling,et al.  Tenofovir-Associated Fanconi Syndrome in Patients with Chronic Hepatitis B Monoinfection , 2013, Antiviral therapy.

[88]  M. Tsai,et al.  Hepatitis B virus (HBV) coinfection accelerates immunologic progression in patients with primary HIV infection in an area of hyperendemicity for HBV infection. , 2013, The Journal of infectious diseases.

[89]  G. Mieli-Vergani,et al.  Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines: consensus of an expert panel on behalf of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition. , 2013, Journal of hepatology.

[90]  Y. Liaw,et al.  Response‐guided peginterferon therapy in hepatitis B e antigen‐positive chronic hepatitis B using serum hepatitis B surface antigen levels , 2013, Hepatology.

[91]  B. van Hoek,et al.  Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective. , 2013, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[92]  Sheng-Nan Lu,et al.  Virological response to entecavir reduces the risk of liver disease progression in nucleos(t)ide analogue-experienced HBV-infected patients with prior resistant mutants. , 2013, The Journal of antimicrobial chemotherapy.

[93]  Han‐Chieh Lin,et al.  The role of mTOR inhibitors in the treatment of hepatocellular carcinoma , 2013, Liver international : official journal of the International Association for the Study of the Liver.

[94]  Shou-Dong Lee,et al.  Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  Sheng-Nan Lu,et al.  A comparison of 4-year entecavir efficacy in nucleos(t)ide analog-naïve and -experienced adult Taiwanese chronic hepatitis B patients , 2013, Hepatology International.

[96]  M. Buti,et al.  Entecavir and Hepatitis B Immune Globulin in Patients Undergoing Liver Transplantation for Chronic Hepatitis B , 2013, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[97]  Yoshiyuki Suzuki,et al.  Long‐term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection , 2013, Hepatology.

[98]  S. Fan,et al.  Oral Nucleoside/Nucleotide Analogs Without Hepatitis B Immune Globulin After Liver Transplantation for Hepatitis B , 2013, The American Journal of Gastroenterology.

[99]  J. Kao,et al.  Hepatitis B viral factors and treatment responses in chronic hepatitis B. , 2013, Journal of the Formosan Medical Association = Taiwan yi zhi.

[100]  S. Pungpapong,et al.  Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation , 2013, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[101]  Ding‐Shinn Chen,et al.  Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow‐up , 2013, Hepatology.

[102]  M. Lai,et al.  Treatment of patients with dual hepatitis C and B by peginterferon α and ribavirin reduced risk of hepatocellular carcinoma and mortality , 2013, Gut.

[103]  H. Lee,et al.  Randomized Trial of the Virologic Response during up to Two Years of Entecavir-Adefovir Combination Therapy in Multiple-Drug-Refractory Chronic Hepatitis B Virus Patients , 2013, Antimicrobial Agents and Chemotherapy.

[104]  P. Marcellin,et al.  Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load , 2013, Hepatology.

[105]  V. Wong,et al.  Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment. , 2013, Gastroenterology.

[106]  Chien-Jen Chen,et al.  A predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection. , 2013, Journal of hepatology.

[107]  A. Boonstra,et al.  Serum levels of interferon-gamma-inducible protein 10 and response to peginterferon therapy in HBeAg-positive chronic hepatitis B. , 2013, Journal of hepatology.

[108]  J. Kao,et al.  Global Perspective on the Natural History of Chronic Hepatitis B: Role of Hepatitis B Virus Genotypes A to J , 2013, Seminars in Liver Disease.

[109]  Kenta Yamamoto,et al.  Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis. , 2013, Journal of hepatology.

[110]  Ding‐Shinn Chen,et al.  Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon‐induced hepatitis B e antigen seroconversion , 2013, Hepatology.

[111]  P. Angus,et al.  Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen–positive liver transplant candidates , 2013, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[112]  R. De Francesco,et al.  IL28B polymorphisms predict interferon‐related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen–negative patients with chronic hepatitis B , 2013, Hepatology.

[113]  John F. Flaherty,et al.  Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study , 2013, The Lancet.

[114]  E. Cholongitas,et al.  High Genetic Barrier Nucleos(t)ide Analogue(s) for Prophylaxis From Hepatitis B Virus Recurrence After Liver Transplantation: A Systematic Review , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[115]  Ding‐Shinn Chen,et al.  Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads , 2013, Hepatology.

[116]  M. Manns,et al.  Treatment Options for Hepatitis Delta Virus Infection , 2013, Current Infectious Disease Reports.

[117]  F. Zoulim,et al.  Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance , 2013, Liver international : official journal of the International Association for the Study of the Liver.

[118]  H. Marusawa,et al.  Efficacy and safety of prophylaxis with entecavir and hepatitis B immunoglobulin in preventing hepatitis B recurrence after living‐donor liver transplantation , 2013, Hepatology research : the official journal of the Japan Society of Hepatology.

[119]  P. Pang,et al.  Randomized, placebo‐controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B , 2012, Hepatology.

[120]  T. Tseng,et al.  Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog , 2012, Journal of gastroenterology.

[121]  H. Blum,et al.  Renal grafts from anti‐hepatitis B core‐positive donors: a quantitative review of the literature , 2012, Transplant infectious disease : an official journal of the Transplantation Society.

[122]  Huy A. Nguyen,et al.  Tenofovir Monotherapy and Tenofovir Plus Entecavir Combination as Rescue Therapy for Entecavir Partial Responders , 2012, Digestive Diseases and Sciences.

[123]  D. Vassilopoulos,et al.  Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. , 2012, Gastroenterology.

[124]  Huy Trinh,et al.  Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B. , 2012, Gastroenterology.

[125]  P. Lampertico,et al.  Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B , 2012, Gut.

[126]  U. Kalus,et al.  Comparative infectious serology testing of pre- and post-mortem blood samples from cornea donors , 2012, Cell and Tissue Banking.

[127]  L. Settas,et al.  Reactivation of occult hepatitis B virus infection, following treatment of refractory rheumatoid arthritis with abatacept. , 2012, Journal of hepatology.

[128]  Jia-Horng Kao,et al.  Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update , 2012, Hepatology International.

[129]  D. Jamieson,et al.  HIV-HBV coinfection--a global challenge. , 2012, The New England journal of medicine.

[130]  Ding-Shinn Chen,et al.  High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. , 2012, Gastroenterology.

[131]  Chien-Jen Chen,et al.  Incidence and determinants of spontaneous seroclearance of hepatitis B e antigen and DNA in patients with chronic hepatitis B. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[132]  P. Lampertico,et al.  Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. , 2012, Journal of hepatology.

[133]  T. Hu,et al.  A Novel Experience of Antiviral Therapy for Chronic Hepatitis B in Renal Transplant Recipients , 2012, Antiviral therapy.

[134]  M. Buti,et al.  Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis , 2012, Gut.

[135]  Chao-Hung Hung,et al.  The therapeutic response of antiviral therapy in HBsAg-positive renal transplant recipients and a long-term follow-up , 2012, Hepatology International.

[136]  P. Marcellin,et al.  Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients , 2012, Hepatology International.

[137]  C. Bunchorntavakul,et al.  Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir , 2012, Journal of viral hepatitis.

[138]  M. Buti,et al.  Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study. , 2012, Journal of hepatology.

[139]  A. Uitterlinden,et al.  Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. , 2012, Gastroenterology.

[140]  Alessandro Nanni Costa,et al.  Liver transplantation from hepatitis B surface antigen positive donors: a safe way to expand the donor pool. , 2012, Journal of hepatology.

[141]  Quanjiang Dong,et al.  Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis B-related fibrosis: a leading meta-analysis , 2012, BMC Gastroenterology.

[142]  C. Peng,et al.  Early serum HBsAg level as a strong predictor of sustained response to peginterferon alfa‐2a in HBeAg‐negative chronic hepatitis B , 2012, Alimentary pharmacology & therapeutics.

[143]  Helen M. Chun,et al.  Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters. , 2012, The Journal of infectious diseases.

[144]  A. Bertoletti,et al.  Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection , 2011, Gut.

[145]  P. Marcellin,et al.  Shorter durations and lower doses of peginterferon alfa‐2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C , 2011, Hepatology.

[146]  M. Winters,et al.  HIV-HBV vaccine escape mutant infection with loss of HBV surface antibody and persistent HBV viremia on tenofovir/emtricitabine without antiviral resistance. , 2011, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[147]  M. Yuen,et al.  Quantitative Hepatitis B Surface Antigen Levels in Patients With Chronic Hepatitis B After 2 Years of Entecavir Treatment , 2011, The American Journal of Gastroenterology.

[148]  M. Yuen,et al.  Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. , 2011, Gastroenterology.

[149]  Chien-Jen Chen,et al.  Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[150]  Ding‐Shinn Chen.  Fighting against viral hepatitis: Lessons from Taiwan , 2011, Hepatology.

[151]  M. Buti,et al.  Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response , 2011, Hepatology.

[152]  H. Wedemeyer,et al.  Hepatitis delta virus , 2011, The Lancet.

[153]  M. Yuen,et al.  Three Years of Continuous Entecavir Therapy in Treatment-Naïve Chronic Hepatitis B Patients: VIRAL Suppression, Viral Resistance, and Clinical Safety , 2011, The American Journal of Gastroenterology.

[154]  Ding‐Shinn Chen,et al.  Effect of Host and Viral Factors on Hepatitis B E Antigen-Positive Chronic Hepatitis B Patients Receiving Pegylated Interferon-α-2A Therapy , 2011, Antiviral therapy.

[155]  Y. Liaw,et al.  Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: A randomized, open‐label study , 2011, Hepatology.

[156]  T. Hsieh,et al.  Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy , 2011, Annals of the rheumatic diseases.

[157]  Paul L. Martin,et al.  Impact of pre-existing hepatitis B infection on the outcomes of kidney transplant recipients in the United States. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[158]  Vincent Wai-Sun Wong,et al.  Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. , 2011, The Lancet. Oncology.

[159]  S. Belknap,et al.  Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[160]  F. Carrat,et al.  Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial. , 2011, JAMA.

[161]  P. Marcellin,et al.  Alpha‐fetoprotein should be included in the hepatocellular carcinoma surveillance guidelines of the american association for the study of liver diseases , 2011, Hepatology.

[162]  H. Goto,et al.  Different effect of HBV vaccine after liver transplantation between chronic HBV carriers and non-HBV patients who received HBcAb-positive grafts , 2011, Journal of Gastroenterology.

[163]  V. Wong,et al.  Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B. , 2011, Journal of hepatology.

[164]  M. Manns,et al.  Peginterferon plus adefovir versus either drug alone for hepatitis delta. , 2011, The New England journal of medicine.

[165]  M. Buti,et al.  Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease , 2011, Hepatology.

[166]  F. Carrat,et al.  Management and treatment of chronic hepatitis B virus infection in HIV positive and negative patients: the EPIB 2008 study. , 2010, Journal of hepatology.

[167]  R. D. de Man,et al.  Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus. , 2010, Gastroenterology.

[168]  C. Boucher,et al.  Prediction of sustained response to peginterferon alfa‐2b for hepatitis B e antigen–positive chronic hepatitis B using on‐treatment hepatitis B surface antigen decline , 2010, Hepatology.

[169]  T. Berg,et al.  Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronic-hepatitis B virus infection. , 2010, Gastroenterology.

[170]  E. Schiff,et al.  Long‐term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B , 2010, Hepatology.

[171]  Y. Ni,et al.  Lamivudine treatment in infantile fulminant hepatitis B , 2010, Pediatrics international : official journal of the Japan Pediatric Society.

[172]  Chien-Jen Chen,et al.  Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study. , 2010, Gastroenterology.

[173]  M. Brunetto,et al.  Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. , 2010, Gastroenterology.

[174]  Pablo Barreiro,et al.  Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapy , 2010, Antiviral therapy.

[175]  R. Tur-kaspa,et al.  Prevention of recurrent hepatitis B virus infection after liver transplantation: hepatitis B immunoglobulin, antiviral drugs, or both? Systematic review and meta‐analysis , 2010, Transplant infectious disease : an official journal of the Transplantation Society.

[176]  Y. Liaw,et al.  Hepatitis B virus DNA level predicts hepatic decompensation in patients with acute exacerbation of chronic hepatitis B. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[177]  V. Wong,et al.  Durability of peginterferon alfa‐2b treatment at 5 years in patients with hepatitis B e antigen–positive chronic hepatitis B , 2010, Hepatology.

[178]  K. Tanikawa,et al.  Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection. , 2010, Journal of hepatology.

[179]  Chien-Jen Chen,et al.  Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[180]  V. Wong,et al.  Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[181]  S. Saab,et al.  Comparison of different immunoprophylaxis regimens after liver transplantation with hepatitis B core antibody–positive donors: A systematic review , 2010, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[182]  T. Chan,et al.  Response to adefovir or entecavir in renal allograft recipients with hepatitic flare due to lamivudine‐resistant hepatitis B , 2010, Clinical transplantation.

[183]  Antonio Bertoletti,et al.  A longitudinal analysis of innate and adaptive immune profile during hepatic flares in chronic hepatitis B. , 2010, Journal of hepatology.

[184]  Ching-Lung Lai,et al.  Entecavir treatment for up to 5 years in patients with hepatitis B e antigen–positive chronic hepatitis B , 2010, Hepatology.

[185]  H. Lee,et al.  Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis. , 2010, Journal of hepatology.

[186]  A. Burroughs,et al.  Liver grafts from anti-hepatitis B core positive donors: a systematic review. , 2010, Journal of hepatology.

[187]  T. Berg,et al.  Long‐term efficacy of tenofovir monotherapy for hepatitis B virus‐monoinfected patients after failure of nucleoside/nucleotide analogues , 2010, Hepatology.

[188]  U. Mihm,et al.  Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function , 2009, Hepatology.

[189]  E. Steyerberg,et al.  Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. , 2009, Gastroenterology.

[190]  Shou-Dong Lee,et al.  Risk factors for early and late recurrence in hepatitis B-related hepatocellular carcinoma. , 2009, Journal of hepatology.

[191]  L. Demelia,et al.  A randomized controlled trial of pegylated interferon-α2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B , 2009, Antiviral therapy.

[192]  P. Komolmit,et al.  Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B. , 2009, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[193]  B. McMahon,et al.  Chronic hepatitis B: Update 2009 , 2009, Hepatology.

[194]  Ding‐Shinn Chen,et al.  Dual chronic hepatitis B virus and hepatitis C virus infection , 2009, Hepatology international.

[195]  G. Cao,et al.  Associations Between Hepatitis B Virus Mutations and the Risk of Hepatocellular Carcinoma: A Meta-Analysis , 2009, Journal of the National Cancer Institute.

[196]  H. Jiang,et al.  Kidney Transplantation from Hepatitis B Surface Antigen Positive Donors into Hepatitis B Surface Antibody Positive Recipients: A Prospective Nonrandomized Controlled Study from a Single Center , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[197]  P. Marcellin,et al.  Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. , 2009, Gastroenterology.

[198]  C. Thio.  Hepatitis B and human immunodeficiency virus coinfection , 2009, Hepatology.

[199]  Y. Kamatani,et al.  A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians , 2009, Nature Genetics.

[200]  Ronald E. Rose,et al.  Long‐term monitoring shows hepatitis B virus resistance to entecavir in nucleoside‐naïve patients is rare through 5 years of therapy , 2009, Hepatology.

[201]  D. Xiu,et al.  Lamivudine or lamivudine combined with hepatitis B immunoglobulin in prophylaxis of hepatitis B recurrence after liver transplantation: a meta‐analysis , 2009, Transplant international : official journal of the European Society for Organ Transplantation.

[202]  T. Asselah,et al.  Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa‐2a in HBeAg‐negative patients , 2009, Hepatology.

[203]  C. Chu,et al.  Hepatitis B virus infection , 2009, The Lancet.

[204]  Sheng-Nan Lu,et al.  The role of HBV genotype, core promoter and precore mutations in advanced liver disease in renal transplant recipients. , 2009, Journal of hepatology.

[205]  Edwin P Hui,et al.  Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[206]  Y. Jeng,et al.  Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. , 2009, Gastroenterology.

[207]  Huy Trinh,et al.  Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. , 2008, The New England journal of medicine.

[208]  Y. Liaw,et al.  Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success. , 2008, Best practice & research. Clinical gastroenterology.

[209]  V. Soriano,et al.  Risks and benefits of using antiretroviral therapy in HIV-infected patients with chronic hepatitis B in developing regions. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[210]  P. Angus,et al.  A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post–liver transplantation hepatitis B prophylaxis , 2008, Hepatology.

[211]  H. Hsu,et al.  Interferon‐α treatment in children and young adults with chronic hepatitis B: a long‐term follow‐up study in Taiwan , 2008, Liver international : official journal of the International Association for the Study of the Liver.

[212]  A. Lok,et al.  How to diagnose and treat hepatitis B virus antiviral drug resistance in the liver transplant setting , 2008, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[213]  Chien-Jen Chen,et al.  Associations Between Hepatitis B Virus Genotype and Mutants and the Risk of Hepatocellular Carcinoma , 2008, Journal of the National Cancer Institute.

[214]  K. Simon,et al.  Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. , 2008, Gastroenterology.

[215]  N. Warner,et al.  The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound , 2008, Hepatology.

[216]  Karen G. Smith,et al.  Hepatitis B immunoglobulin and Lamivudine improve hepatitis B-related outcomes after liver transplantation: meta-analysis. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[217]  A. Bertoletti,et al.  Understanding the immunopathogenesis of chronic hepatitis B virus: An Asian prospective , 2008, Journal of gastroenterology and hepatology.

[218]  D. Samuel,et al.  Hepatocellular carcinoma is associated with an increased risk of hepatitis B virus recurrence after liver transplantation. , 2008, Gastroenterology.

[219]  J. García-Samaniego,et al.  [Hepatitis B in patients with HIV infection]. , 2008, Enfermedades infecciosas y microbiologia clinica.

[220]  C. Hsiung,et al.  A revisit of prophylactic lamivudine for chemotherapy‐associated hepatitis B reactivation in non‐Hodgkin's lymphoma: A randomized trial , 2008, Hepatology.

[221]  G. Lau,et al.  Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B , 2008, Hepatology international.

[222]  D. Hasenclever,et al.  Should Treatment of Hepatitis B Depend on Hepatitis B virus Genotypes? A Hypothesis Generated from an Explorative Analysis of Published Evidence , 2008, Antiviral therapy.

[223]  P. Marcellin,et al.  HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa‐2a for HBeAg‐positive chronic hepatitis B , 2008, Hepatology.

[224]  R. Bruno,et al.  European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV‐infected adults , 2008, HIV medicine.

[225]  G. Fattovich,et al.  Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. , 2008, Journal of hepatology.

[226]  N. Nikolaidis,et al.  Lamivudine/pegylated interferon alfa‐2b sequential combination therapy compared with lamivudine monotherapy in HBeAg‐negative chronic hepatitis B , 2007, Journal of gastroenterology and hepatology.

[227]  M. Buti,et al.  Adherence to Lamivudine after an early withdrawal of hepatitis B immune globulin plays an important role in the long-term prevention of hepatitis B virus recurrence. , 2007, Transplantation.

[228]  M. Buti,et al.  Peginterferon alpha‐2b is safe and effective in HBeAg‐positive chronic hepatitis B patients with advanced fibrosis , 2007, Hepatology.

[229]  Ding‐Shinn Chen,et al.  Association of pre‐S deletion mutant of hepatitis B virus with risk of hepatocellular carcinoma , 2007, Journal of gastroenterology and hepatology.

[230]  V. Soriano,et al.  Immunizations in HIV-infected adults. , 2007, AIDS reviews.

[231]  V. Wong,et al.  Virological Response to Different Combination Regimes of Peginterferon α-2b and Lamivudine in Hepatitis B e Antigen Positive Chronic Hepatitis B , 2007, Antiviral therapy.

[232]  Lin Shen,et al.  The HBV drug entecavir - effects on HIV-1 replication and resistance. , 2007, The New England journal of medicine.

[233]  John Wong,et al.  Identification of hepatitis B virus–specific lymphocytes in human liver grafts from HBV‐immune donors , 2007, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[234]  M. Lai,et al.  Clinicopathological differences between hepatitis B viral genotype B‐ and C‐related resectable hepatocellular carcinoma , 2007, Journal of viral hepatitis.

[235]  A. Concejero,et al.  Active Immunization to Prevent De Novo Hepatitis B Virus Infection in Pediatric Live Donor Liver Recipients , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[236]  E. Cholongitas,et al.  New insights into the coagulopathy of liver disease and liver transplantation. , 2006, World journal of gastroenterology.

[237]  P. Marcellin,et al.  Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B , 2006, Gut.

[238]  M. Kramer,et al.  Lamivudine prophylaxis for hepatitis B virus infection after lung transplantation. , 2006, The Annals of thoracic surgery.

[239]  Ding‐Shinn Chen,et al.  High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases. , 2006, Gastroenterology.

[240]  Chien-Jen Chen,et al.  Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. , 2006, Gastroenterology.

[241]  D. Vergani,et al.  Combined lamivudine/interferon-alpha treatment in "immunotolerant" children perinatally infected with hepatitis B: a pilot study. , 2006, The Journal of pediatrics.

[242]  Guan-Tarn Huang,et al.  Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. , 2006, JAMA.

[243]  S. Hadziyannis,et al.  A partially overlapping treatment course with lamivudine and interferon in hepatitis B e antigen‐negative chronic hepatitis B , 2006, Alimentary pharmacology & therapeutics.

[244]  F. Fabrizi,et al.  HBsAg Seropositive Status and Survival After Renal Transplantation: Meta‐Analysis of Observational Studies , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[245]  Ding‐Shinn Chen,et al.  Natural course and treatment of dual hepatitis B virus and hepatitis C virus infections. , 2005, Journal of the Formosan Medical Association = Taiwan yi zhi.

[246]  J. Angel,et al.  Reactivation of hepatitis B infection following allogeneic bone marrow transplantation in a hepatitis B-immune patient: case report and review of the literature. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[247]  Y. Jeng,et al.  Lamivudine treatment in maternally transmitted chronic hepatitis B virus infection patients , 2005, Pediatrics international : official journal of the Japan Pediatric Society.

[248]  S. Fan,et al.  Failure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B. , 2005, Journal of hepatology.

[249]  F. Tacke,et al.  Selection of Hepatitis B Virus Polymerase Mutations in HIV-Coinfected Patients Treated with Tenofovir , 2005, Antiviral therapy.

[250]  N. Leung,et al.  Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy , 2005, Gut.

[251]  Thomas Berg,et al.  Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. , 2005, The New England journal of medicine.

[252]  W. Au,et al.  Effectiveness of Prophylactic Anti‐HBV Therapy in Allogeneic Hematopoietic Stem Cell Transplantation with HBsAg Positive Donors , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[253]  M. Rizzetto,et al.  Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[254]  V. Wong,et al.  A Randomized, Controlled Trial of Combination Therapy for Chronic Hepatitis B: Comparing Pegylated Interferon-2b and Lamivudine with Lamivudine Alone , 2005, Annals of Internal Medicine.

[255]  G. Gerken,et al.  Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial , 2005, The Lancet.

[256]  Francesco Donato,et al.  Hepatocellular carcinoma in cirrhosis: incidence and risk factors. , 2004, Gastroenterology.

[257]  P. Marcellin,et al.  Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. , 2004, The New England journal of medicine.

[258]  W. Kim,et al.  Outcome of liver transplantation for hepatitis B in the United States , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[259]  C. Chu,et al.  Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. , 2004, The American journal of medicine.

[260]  R. Purcell,et al.  Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. , 2004, Gastroenterology.

[261]  C. Hung,et al.  Impact of chronic hepatitis B virus (HBV) infection on outcomes of patients infected with HIV in an area where HBV infection is hyperendemic. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[262]  C. Chu,et al.  Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. , 2004, Gastroenterology.

[263]  W. Yeo,et al.  Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy , 2004, British Journal of Cancer.

[264]  P. Neuhaus,et al.  Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B‐related disease , 2003, Hepatology.

[265]  Y. Chao,et al.  Peginterferon α‐2a (40 kDa): an advance in the treatment of hepatitis B e antigen‐positive chronic hepatitis B , 2003, Journal of viral hepatitis.

[266]  M. Buti,et al.  A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. , 2003, Journal of hepatology.

[267]  J. Whang‐Peng,et al.  Steroid‐free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV‐carriers with lymphoma , 2003, Hepatology.

[268]  Y. Liaw,et al.  The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B , 2003 .

[269]  Y. Liaw,et al.  The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B. , 2003, Journal of hepatology.

[270]  Ding‐Shinn Chen,et al.  Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. , 2003, Gastroenterology.

[271]  T. Chan,et al.  Preemptive lamivudine therapy based on HBV DNA level in HBsAg‐positive kidney allograft recipients , 2002, Hepatology.

[272]  E. Christensen,et al.  Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients , 2002, American Journal of Gastroenterology.

[273]  E. Sagnelli,et al.  HBV superinfection in hepatitis C virus chronic carriers, viral interaction, and clinical course , 2002, Hepatology.

[274]  J. Phair,et al.  HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS) , 2002, The Lancet.

[275]  Ding‐Shinn Chen,et al.  Genotypes and Clinical Phenotypes of Hepatitis B Virus in Patients with Chronic Hepatitis B Virus Infection , 2002, Journal of Clinical Microbiology.

[276]  D. Samuel,et al.  Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors , 2002, Gut.

[277]  D. Thabut,et al.  Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: Results of a pilot study , 2001, Hepatology.

[278]  Chi-hung Cheng,et al.  Long-Term Impact of Hepatitis B, C Virus Infection on Renal Transplantation , 2001, American Journal of Nephrology.

[279]  R. Chung,et al.  Approach to the Management of Allograft Recipients Following the Detection of Hepatitis B Virus in the Prospective Organ Donor , 2001, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[280]  B. Portmann,et al.  Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation. , 2001, Journal of hepatology.

[281]  G. Ogg,et al.  Lamivudine treatment can overcome cytotoxic T‐cell hyporesponsiveness in chronic hepatitis B: New perspectives for immune therapy , 2001, Hepatology.

[282]  W. Yang,et al.  RESULTS ON PREEMPTIVE OR PROPHYLACTIC TREATMENT OF LAMIVUDINE IN HBsAg (+) RENAL ALLOGRAFT RECIPIENTS: COMPARISON WITH SALVAGE TREATMENT AFTER HEPATIC DYSFUNCTION WITH HBV RECURRENCE , 2001, Transplantation.

[283]  Ding‐Shinn Chen,et al.  Hepatitis B genotypes and the response to interferon therapy. , 2000, Journal of hepatology.

[284]  L. Stuyver,et al.  Hepatitis virus infections in heart transplant recipients: epidemiology, natural history, characteristics, and impact on survival. , 2000, Gastroenterology.

[285]  M. Cinquegrani,et al.  Outcomes in patients who are hepatitis B surface antigen-positive before transplantation: an analysis and study using the joint ISHLT/UNOS thoracic registry. , 2000, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[286]  Ding‐Shinn Chen,et al.  Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. , 2000, Gastroenterology.

[287]  M. Loriot,et al.  Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men , 1999, Hepatology.

[288]  P Coriat,et al.  Impact of hepatitis B and C virus on kidney transplantation outcome , 1999, Hepatology.

[289]  J. Markmann,et al.  Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin , 1998, Hepatology.

[290]  P Boffetta,et al.  A meta‐analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma , 1998, International journal of cancer.

[291]  B. Scharschmidt,et al.  Hepatitis B in Patients with HIV Infection: Relationship to AIDS and Patient Survival , 1992, Annals of Internal Medicine.

[292]  P. Magnus,et al.  Hepatitis B antibodies in HIV‐infected homosexual men are associated with more rapid progression to AIDS , 1992, AIDS.

[293]  D. Cooper,et al.  The influence of human immunodeficiency virus type 1 infection on the development of the hepatitis B virus carrier state. , 1991, The Journal of infectious diseases.

[294]  D. Samuel,et al.  Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients , 1991, The Lancet.

[295]  H. Thomas,et al.  Natural history of chronic hepatitis B virus infection in taiwan: Studies of hepatitis B virus DNA in serum , 1985, Hepatology.

[296]  Pamela G. Guren,et al.  Candidates , 1982, Otolaryngology–Head and Neck Surgery.

[297]  John F. Flaherty,et al.  Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. , 2016, The lancet. Gastroenterology & hepatology.

[298]  M. Buti,et al.  Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients With Chronic Hepatitis B. , 2016, Gastroenterology.

[299]  Y. Falck‐Ytter,et al.  American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Reactivation During Immunosuppressive Drug Therapy , 2014 .

[300]  M. Manns,et al.  Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy. , 2015, Journal of hepatology.

[301]  Min Chen,et al.  Comparison of acoustic radiation force impulse imaging and transient elastography for non-invasive assessment of liver fibrosis in patients with chronic hepatitis B. , 2015, Ultrasound in medicine & biology.

[302]  N. Selzner,et al.  One year of hepatitis B immunoglobulin plus tenofovir therapy is safe and effective in preventing recurrent hepatitis B post-liver transplantation. , 2014, Canadian journal of gastroenterology & hepatology.

[303]  N. Selzner,et al.  One Year of Hepatitis B Immunoglobulin Plus Tenofovir Therapy is Safe and Effective in Preventing Recurrent Hepatitis B Infection Post-Liver Transplantation , 2014 .

[304]  S. Shah,et al.  Liver transplantation from hepatitis B surface antigen-positive donors. , 2013, Transplantation proceedings.

[305]  高嘉宏,et al.  Sustained hcv clearance and increased HBsAg seroclearance in patients with dual chronic hepatitis C and B during post-treatment follow-up. , 2013 .

[306]  EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. , 2012, Journal of hepatology.

[307]  P. Calès,et al.  Resolution of chronic hepatitis Delta after 1 year of combined therapy with pegylated interferon, tenofovir and emtricitabine. , 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[308]  Norman Gitlin,et al.  Chronic hepatitis B : an update , 2010 .

[309]  F. Zoulim,et al.  Hepatitis B: reflections on the current approach to antiviral therapy. , 2008, Journal of hepatology.

[310]  P. Loehrer,et al.  Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level , 2007 .

[311]  M. Campbell.  Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis BLau GKK, for the Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group (Univ of Hong Kong, China; et al) N Engl J Med 352:2682–2695, 2005§ , 2006 .

[312]  Ding‐Shinn Chen,et al.  Hepatitis B genotypes correlate with tumor recurrence after curative resection of hepatocellular carcinoma. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[313]  E. Schiff,et al.  Histological outcome during long-term lamivudine therapy. , 2003, Gastroenterology.

[314]  F. Chisari,et al.  Hepatitis B virus immunopathogenesis. , 1995, Annual review of immunology.

[315]  S. Davies,et al.  Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. , 1992, Journal of hepatology.

[316]  A. Lok,et al.  Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. , 1991 .